| scholarly article | Q13442814 |
| P50 | author | Peter J Whorwell | Q56557233 |
| P2093 | author name string | J Morris | |
| A Agrawal | |||
| S Jakob | |||
| D Guyonnet | |||
| L A Houghton | |||
| A Schlumberger | |||
| B Reilly | |||
| N Goupil Feuillerat | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irritable bowel syndrome | Q838966 |
| Bifidobacterium lactis | Q62854400 | ||
| P304 | page(s) | 104-114 | |
| P577 | publication date | 2008-09-17 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation | |
| P478 | volume | 29 |
| Q93006521 | A Fermented Milk Product with B. Lactis CNCM I-2494 and Lactic Acid Bacteria Improves Gastrointestinal Comfort in Response to a Challenge Diet Rich in Fermentable Residues in Healthy Subjects |
| Q41432703 | A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation |
| Q52620911 | A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. |
| Q33457416 | A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. |
| Q46116511 | A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms |
| Q37907937 | Abdominal bloating and distension: what is the role of the microbiota. |
| Q38040321 | Agents that act luminally to treat diarrhoea and constipation |
| Q38864862 | Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis |
| Q38236812 | American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation |
| Q36875133 | Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice |
| Q38783848 | Bloating and Abdominal Distension: Old Misconceptions and Current Knowledge |
| Q31054269 | British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults |
| Q38858071 | British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). |
| Q38855986 | British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). |
| Q34409219 | Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. |
| Q34882090 | Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation |
| Q34162526 | Changes of the human gut microbiome induced by a fermented milk product |
| Q55312184 | Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. |
| Q46324386 | Close association between intestinal microbiota and irritable bowel syndrome |
| Q34551320 | Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths? |
| Q24633140 | Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment) |
| Q60707789 | Consumption of a Fermented Milk Product Containing Bifidobacterium lactis CNCM I-2494 in Women Complaining of Minor Digestive Symptoms: Rapid Response Which Is Independent of Dietary Fibre Intake or Physical Activity |
| Q37340274 | Consumption of fermented milk product with probiotic modulates brain activity |
| Q24658598 | Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit |
| Q24601092 | Current level of consensus on probiotic science--report of an expert meeting--London, 23 November 2009 |
| Q89171698 | Differences in gut microbiota associated with age, sex, and stool consistency in healthy Japanese subjects |
| Q34409031 | Do probiotics improve symptoms in patients with irritable bowel syndrome? |
| Q38619718 | Does the scientific evidence support the advertising claims made for products containing Lactobacillus casei and Bifidobacterium lactis? A systematic review. |
| Q36214586 | Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis |
| Q33419501 | Effect of the consumption of a fermented dairy product containing Bifidobacterium lactis DN-173 010 on constipation in childhood: a multicentre randomised controlled trial (NTRTC: 1571). |
| Q36426025 | Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis |
| Q28084745 | Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis |
| Q43355225 | Effects of a probiotic fermented milk on functional constipation: a randomized, double-blind, placebo-controlled study |
| Q92132034 | Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis |
| Q28244815 | Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis |
| Q39455595 | Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation |
| Q64077956 | Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome |
| Q33443147 | Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study |
| Q64096081 | Forty-five-year evolution of probiotic therapy |
| Q61798328 | Functional gastrointestinal disorders and gut-brain axis: What does the future hold? |
| Q35274586 | Genome sequence of the probiotic strain Bifidobacterium animalis subsp. lactis CNCM I-2494. |
| Q34119622 | Genomic insights into bifidobacteria |
| Q37682520 | Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome |
| Q90729716 | Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik |
| Q26768550 | Gut microbiota role in irritable bowel syndrome: New therapeutic strategies |
| Q33456428 | IBS and the role of otilonium bromide |
| Q31158955 | Identification of restriction-modification systems of Bifidobacterium animalis subsp. lactis CNCM I-2494 by SMRT sequencing and associated methylome analysis |
| Q24631357 | Intestinal microbiota in functional bowel disorders: a Rome foundation report |
| Q27001712 | Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis |
| Q38014500 | Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome. |
| Q39018403 | Irritable bowel syndrome: a gut microbiota-related disorder? |
| Q35231621 | Irritable bowel syndrome: the problem and the problem of treating it - is there a role for probiotics? |
| Q64118891 | Lactobacillus casei Strain Shirota Alleviates Constipation in Adults by Increasing the Pipecolinic Acid Level in the Gut |
| Q37190545 | Management Strategies for Abdominal Bloating and Distension |
| Q39238503 | Management of the multiple symptoms of irritable bowel syndrome |
| Q39308242 | Mechanisms of Action of Probiotics and the Gastrointestinal Microbiota on Gut Motility and Constipation |
| Q33616944 | Mismatch between Probiotic Benefits in Trials versus Food Products |
| Q46302916 | Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome |
| Q43316042 | New insights into bloating and abdominal distension: is it all outlet obstruction? |
| Q35404257 | Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial |
| Q36817397 | Primary Care Management of Chronic Constipation in Asia: The ANMA Chronic Constipation Tool |
| Q34978494 | Principles and clinical implications of the brain-gut-enteric microbiota axis |
| Q34725819 | Probiotic Fermented Milk Containing Dietary Fiber Has Additive Effects in IBS with Constipation Compared to Plain Probiotic Fermented Milk |
| Q34591182 | Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells. |
| Q36211712 | Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It? |
| Q35096915 | Probiotic actions on diseases: implications for therapeutic treatments |
| Q33449885 | Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study |
| Q27008982 | Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials |
| Q33730572 | Probiotic treatment of irritable bowel syndrome in children |
| Q36567134 | Probiotics and the gut microbiota in intestinal health and disease |
| Q38162884 | Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis |
| Q38035021 | Probiotics use to treat irritable bowel syndrome |
| Q82596467 | Probiotics: from bench to market |
| Q34245355 | Randomised clinical trial: efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation--a double-blind, controlled, crossover study |
| Q37045717 | Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation |
| Q37973803 | Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria. |
| Q90419350 | Study of the In Vitro Antagonistic Activity of Various Single-Strain and Multi-Strain Probiotics against Escherichia coli |
| Q37671960 | Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population |
| Q33521058 | Systematic review of randomised controlled trials: probiotics for functional constipation |
| Q49822026 | Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus |
| Q37587557 | Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. |
| Q26769725 | THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review |
| Q88765793 | Targeting the Microbiota, from Irritable Bowel Syndrome to Mood Disorders: Focus on Probiotics and Prebiotics |
| Q37627724 | The Effect of Probiotic Yogurt on Constipation in Pregnant Women: A Randomized Controlled Clinical Trial |
| Q57167488 | The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders |
| Q34031406 | The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial |
| Q34309689 | The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures |
| Q37564122 | Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders |
Search more.